Advances in adjuvant systemic therapy for non-small-cell lung cancer  

作　　者：David Leong Rajat Rai Brandon Nguyen Andrew Lee Desmond Yip 

机构地区：[1]Department of Medical Oncology, The Canberra Hospital, Garran, ACT 2605, Australia David Leong, Desmond Yip, ANU Medical School, Australian National University [2]Department of Radiation Oncology, The Canberra Hospital, Yamba Drive, Garran, ACT 2605, Australia

出　　处：《World Journal of Clinical Oncology》2014年第4期633-645,共13页世界临床肿瘤学杂志（英文版）

摘　　要：Non-small-cell lung cancer remains a leading cause of death around the world. For most cases, the only chance of cure comes from resection for localised disease, however relapse rates remain high following surgery. Data has emerged over recent years regarding the utility of adjuvant chemotherapy for improving disease-free and overall survival of patients following curative resection. This paper reviews the clinical trials that have been conducted in this area along with the studies integrating radiation therapy in the adjuvant setting. The role of prognostic gene signatures are reviewed as well as ongoing clinical trials including those incorporating biological or targeted therapies.Non-small-cell lung cancer remains a leading cause of death around the world. For most cases, the only chance of cure comes from resection for localised disease, however relapse rates remain high following surgery. Data has emerged over recent years regarding the utility of adjuvant chemotherapy for improving disease-free and overall survival of patients following curative resection. This paper reviews the clinical trials that have been conducted in this area along with the studies integrating radiation therapy in the adjuvant setting. The role of prognostic gene signatures are reviewed as well as ongoing clinical trials including those incorporating biological or targeted therapies.

关 键 词：CARCINOMA Non-small-cell LUNG CHEMOTHERAPY ADJUVANT RADIOTHERAPY Biological therapy BIOMARKER 

分 类 号：R734.2[医药卫生—肿瘤]